Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
Bio-Techne (NASDAQ: TECH) announced that Kim Kelderman, President and CEO, will present at the 2026 J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced that Kim Kelderman, President and CEO, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PST. A live webcast will be available via the company's Investor Relations Calendar page.
Investors can access the presentation through the IR Calendar on Bio-Techne's investor relations website.
Details
News Market Reaction – TECH
On Dec 23, the day this news came out, TECH closed 0.49% above the previous close.
Data tracked by StockTitan Argus for the Dec 23 session.
Key Figures
- Conference date
- January 13, 2026
- J.P. Morgan Healthcare Conference presentation date
- Presentation time
- 9:00 a.m. PST
- Scheduled start time for conference presentation
Historical Context
-
Collaboration to develop automated 3D multiomic spatial biology workflow.
-
Launch of enhanced Leo System for higher-throughput multiplex protein analysis.
-
Announcement of three upcoming investor conference presentations in early December.
-
Licensing of AI-designed NovoBody Duo molecules to expand protein portfolio.
-
Scheduling of four November healthcare investor conference presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact: | David Clair, Vice President, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-2026-jp-morgan-healthcare-conference-302648108.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.